At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ICAD icad
Pre-Market Trading 01-07 04:04:53 EST
2.02
-0.04
-1.94%
High2.06
Low1.97
Vol158.32K
Open2.03
D1 Closing2.06
Amplitude4.37%
Mkt Cap53.24M
Tradable Cap50.14M
Total Shares26.35M
T/O317.39K
T/O Rate0.64%
Tradable Shares24.82M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
SABCS 2024: New Research Assesses iCAD’s Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations
Corrected-(Official)-ICAD Advances Fight Against Breast Cancer With FDA-Cleared, Next-Generation AI Solutions & Profound Health Partnership (Not 'Second-Read AI' ) With Cascaid Health
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
ICAD Advances Fight Against Breast Cancer With FDA-Cleared, Next-Generation AI Solutions and a Second-Read AI Partnership With Cascaid Health at Rsna 2024
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.